Sunnyvale, California, U.S., September 30, 2026
Ceribell, Inc., a medical technology company focused on neurological care, has received FDA 510(k) clearance for new software capabilities that expand quantitative electroencephalography (EEG) trending and amplitude-integrated EEG analysis on the Ceribell System. The regulatory milestone strengthens the company’s AI-powered brain monitoring platform and is designed to help clinicians interpret complex EEG information more efficiently at the bedside. The newly cleared software converts hours of brain activity data into simplified, easy-to-read trends, allowing healthcare professionals to identify meaningful changes in neurological activity and make more informed clinical decisions across multiple acute-care settings. Importantly, the new clearance has no age restriction, extending the potential application from premature newborns in neonatal intensive care units to adult patients in emergency departments and intensive care units.
New EEG Software Adds Three Monitoring Capabilities
The FDA-cleared software update introduces three major capabilities to the Ceribell Platform. The first is Alpha-Delta Ratio (ADR) and Relative Alpha (RA) trending, which provides continuous brain monitoring that may help clinicians recognize early signs of brain distress and reduced blood flow in high-risk patients, including those experiencing aneurysmal subarachnoid hemorrhage. Earlier recognition of neurological changes may support more proactive clinical intervention in critical-care environments where rapid assessment is essential. The second capability is Burst Suppression monitoring, which provides a real-time view of brain activity that can assist clinicians in adjusting sedation medications when treating severe ongoing seizures or managing brain swelling. Together, these tools are designed to simplify interpretation of longitudinal EEG information and support faster decision-making at the bedside. The third capability is Amplitude-Integrated EEG (aEEG), which enables simplified, long-term monitoring of background brain activity. The feature is particularly relevant to neonatal care, where continuous assessment of neurological activity can be important in intensive-care settings. By incorporating aEEG into its platform, Ceribell is extending the utility of its technology beyond traditional adult acute-care applications while supporting monitoring needs in the NICU and adult ICU. The absence of an age restriction on the clearance is notable because it allows the same software-based trends to be used across a broad patient population, from premature infants to adults receiving emergency or intensive care.
AI-Powered Platform Expands Neurological Monitoring
Ceribell’s latest FDA clearance builds on the company’s broader development of an AI-powered EEG platform designed for rapid diagnosis and continuous monitoring of patients with serious neurological conditions. The Ceribell System combines portable hardware with software algorithms intended to make EEG monitoring more accessible in acute-care environments. The company has previously received FDA clearances related to neonatal seizure detection and delirium monitoring, demonstrating an ongoing expansion of its platform across neurological and critical-care applications.
Advertisement
Ceribell expects the newly cleared features to be integrated through an automatic software update in the first half of 2027. The company’s expansion of quantitative EEG trending and aEEG analysis reflects the increasing role of digital technologies and artificial intelligence in helping clinicians process complex neurological data. For healthcare providers, faster access to understandable EEG trends could help support timely intervention when neurological status changes rapidly. The clearance therefore represents another step in the development of point-of-care neurological monitoring technology, while expanding Ceribell’s potential reach across neonatal, emergency, and intensive-care environments.
Source: Ceribell press release
